Tabula Rasa Healthcare Inc. (NASDAQ:TRHC)‘s stock had its “overweight” rating reissued by stock analysts at Piper Jaffray Companies in a report issued on Wednesday. They presently have a $20.00 price target on the stock, up from their prior price target of $19.00. Piper Jaffray Companies’ price objective indicates a potential upside of 17.72% from the stock’s previous close.

TRHC has been the topic of several other research reports. Chardan Capital began coverage on shares of Tabula Rasa Healthcare in a report on Monday, July 10th. They set a “buy” rating and a $19.50 target price on the stock. UBS AG reaffirmed a “buy” rating and set a $17.00 target price (down previously from $18.00) on shares of Tabula Rasa Healthcare in a report on Thursday, May 25th. Zacks Investment Research raised shares of Tabula Rasa Healthcare from a “sell” rating to a “hold” rating in a report on Thursday, April 13th. Stifel Nicolaus reduced their target price on shares of Tabula Rasa Healthcare from $19.00 to $16.00 and set a “buy” rating on the stock in a report on Tuesday, May 2nd. Finally, Robert W. Baird increased their price target on shares of Tabula Rasa Healthcare from $17.00 to $18.00 and gave the company an “outperform” rating in a research report on Tuesday. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Tabula Rasa Healthcare has a consensus rating of “Buy” and a consensus target price of $17.83.

Shares of Tabula Rasa Healthcare (NASDAQ TRHC) traded down 2.47% during mid-day trading on Wednesday, reaching $16.99. 95,272 shares of the company’s stock were exchanged. Tabula Rasa Healthcare has a 52-week low of $10.39 and a 52-week high of $17.88. The firm’s market cap is $292.53 million. The company has a 50 day moving average price of $14.71 and a 200 day moving average price of $14.02.

Tabula Rasa Healthcare (NASDAQ:TRHC) last issued its quarterly earnings results on Monday, August 7th. The company reported $0.06 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.06. The firm had revenue of $29.70 million for the quarter, compared to analyst estimates of $27.84 million. Tabula Rasa Healthcare had a negative net margin of 10.27% and a negative return on equity of 12.06%. The company’s revenue was up 32.6% compared to the same quarter last year. Analysts forecast that Tabula Rasa Healthcare will post $0.41 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Piper Jaffray Companies Reiterates Overweight Rating for Tabula Rasa Healthcare Inc. (NASDAQ:TRHC)” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.watchlistnews.com/piper-jaffray-companies-reiterates-overweight-rating-for-tabula-rasa-healthcare-inc-nasdaqtrhc/1466772.html.

In related news, Director Glen R. Bressner bought 7,500 shares of the company’s stock in a transaction dated Thursday, May 18th. The stock was purchased at an average cost of $11.96 per share, with a total value of $89,700.00. Following the transaction, the director now owns 18,256 shares in the company, valued at approximately $218,341.76. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Orsula V. Knowlton sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, July 19th. The stock was sold at an average price of $14.20, for a total transaction of $113,600.00. Following the completion of the sale, the insider now directly owns 903,407 shares of the company’s stock, valued at $12,828,379.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 46,759 shares of company stock valued at $634,444. Corporate insiders own 45.80% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Cadence Capital Management LLC bought a new stake in Tabula Rasa Healthcare during the second quarter valued at approximately $210,000. Bank of New York Mellon Corp boosted its stake in Tabula Rasa Healthcare by 47.2% in the second quarter. Bank of New York Mellon Corp now owns 19,412 shares of the company’s stock valued at $293,000 after buying an additional 6,228 shares in the last quarter. Boston Partners boosted its stake in Tabula Rasa Healthcare by 17.1% in the second quarter. Boston Partners now owns 235,180 shares of the company’s stock valued at $3,540,000 after buying an additional 34,360 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Tabula Rasa Healthcare by 58.1% in the second quarter. Russell Investments Group Ltd. now owns 94,089 shares of the company’s stock valued at $1,415,000 after buying an additional 34,565 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its stake in Tabula Rasa Healthcare by 108.5% in the first quarter. TIAA CREF Investment Management LLC now owns 8,131 shares of the company’s stock valued at $110,000 after buying an additional 4,232 shares in the last quarter. 24.99% of the stock is owned by hedge funds and other institutional investors.

Tabula Rasa Healthcare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Analyst Recommendations for Tabula Rasa Healthcare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.